✦ LIBER ✦

Eliglustat safety profile based on a pooled analysis of data from four trials in Gaucher disease type I

✍ Scribed by Ross, Leorah; Peterschmitt, Judith; Puga, Ana C.; Cox, Gerald F.; Marulkar, Sachin; Angell, Jennifer; Gaemers, Bas; Mankoski, Raymond

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of linagliptin:

✍ G. Schernthaner; A. H. Barnett; A. Emser; S. Patel; J. Troost; H.-J. Woerle; M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

Lipid-altering efficacy and safety profi

✍ L. A. Leiter; D. J. Betteridge; M. Farnier; J. R. Guyton; J. Lin; A. Shah; A. O. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 645 KB

Consistent evidence of activity of ectei

✍ A. Le Cesne; J.L. Misset; G. Demetri; J.A. Lopez-Martin; J.Y. Blay; A. van Ooste 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 172 KB

PREDICTION OF RECURRENCE AND PROGRESSION

✍ J.M. Fernandez-Gomez; R. Madero; E. Solsona; L. Martinez-Pineiro; M. Gonzalez; R 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB

PDB46 COST-UTILITY OF INSULIN DETEMIR VE

✍ H Scheijbeler; M Aagren; S Nielsen; WJ Valentine; G Goodall; R Kotchie 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB